153 related articles for article (PubMed ID: 30549356)
1. Serum matrix metalloproteinase 8 and tissue inhibitor of metalloproteinase 1: Potential markers for malignant transformation of recurrent respiratory papillomatosis and for prognosis of laryngeal cancer.
Pakkanen PP; Aaltonen LM; Sorsa TA; Tervahartiala TI; Hagström JK; Ilmarinen TT
Head Neck; 2019 Feb; 41(2):309-314. PubMed ID: 30549356
[TBL] [Abstract][Full Text] [Related]
2. Low expression of nuclear Toll-like receptor 4 in laryngeal papillomas transforming into squamous cell carcinoma.
Ilmarinen T; Hagström J; Haglund C; Auvinen E; Leivo I; Pitkäranta A; Aaltonen LM
Otolaryngol Head Neck Surg; 2014 Nov; 151(5):785-90. PubMed ID: 25205638
[TBL] [Abstract][Full Text] [Related]
3. High levels of tissue inhibitor of metalloproteinase-1 (TIMP-1) in the serum are associated with poor prognosis in HPV-negative squamous cell oropharyngeal cancer.
Carpén T; Sorsa T; Jouhi L; Tervahartiala T; Haglund C; Syrjänen S; Tarkkanen J; Mohamed H; Mäkitie A; Hagström J; Mattila PS
Cancer Immunol Immunother; 2019 Aug; 68(8):1263-1272. PubMed ID: 31240326
[TBL] [Abstract][Full Text] [Related]
4. Expression and Concentration of Matrix Metalloproteinase 9 and Tissue Inhibitor of Matrix Metalloproteinases 1 in Laryngeal Squamous Cell Carcinoma.
Matulka M; Konopka A; Mroczko B; Pryczynicz A; Kemona A; Groblewska M; Sieskiewicz A; Olszewska E
Dis Markers; 2019; 2019():3136792. PubMed ID: 31143300
[TBL] [Abstract][Full Text] [Related]
5. Tumor progression driven by pathways activating matrix metalloproteinases and their inhibitors.
Bodnar M; Szylberg Ł; Kazmierczak W; Marszalek A
J Oral Pathol Med; 2015 Jul; 44(6):437-43. PubMed ID: 25244188
[TBL] [Abstract][Full Text] [Related]
6. Expression of matrix metalloproteinases (MMP-2 and MMP-9) in recurrent respiratory papillomas and laryngeal carcinoma: clinical and morphological parallels.
Uloza V; Liutkevičius V; Pangonytė D; Saferis V; Lesauskaitė V
Eur Arch Otorhinolaryngol; 2011 Jun; 268(6):871-8. PubMed ID: 21259063
[TBL] [Abstract][Full Text] [Related]
7. Expression of type IV collagen, metalloproteinase-2, metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in laryngeal squamous cell carcinomas.
Cao XL; Xu RJ; Zheng YY; Liu J; Teng YS; Li Y; Zhu J
Asian Pac J Cancer Prev; 2011; 12(12):3245-9. PubMed ID: 22471461
[TBL] [Abstract][Full Text] [Related]
8. Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer.
Ylisirniö S; Höyhtyä M; Mäkitaro R; Pääakkö P; Risteli J; Kinnula VL; Turpeenniemi-Hujanen T; Jukkola A
Clin Cancer Res; 2001 Jun; 7(6):1633-7. PubMed ID: 11410500
[TBL] [Abstract][Full Text] [Related]
9. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
10. Malignant Transformation of Juvenile Recurrent Respiratory Papillomatosis.
Muhammad Fauzi HG; Mohan Singh AS; Abdul Rahim S; Chooi LL; Ramasamy V; Mohamad Pakarul Razy NH; Mohamad I
Gulf J Oncolog; 2021 May; 1(36):79-81. PubMed ID: 35017141
[TBL] [Abstract][Full Text] [Related]
11. Plasma level of tissue inhibitor of matrix metalloproteinase-1 but not that of matrix metalloproteinase-8 predicts survival in head and neck squamous cell cancer.
Pradhan-Palikhe P; Vesterinen T; Tarkkanen J; Leivo I; Sorsa T; Salo T; Mattila PS
Oral Oncol; 2010 Jul; 46(7):514-8. PubMed ID: 20371206
[TBL] [Abstract][Full Text] [Related]
12. Upregulated TIMP-1 correlates with poor prognosis of laryngeal squamous cell carcinoma.
Ma J; Wang J; Fan W; Pu X; Zhang D; Fan C; Xiong L; Zhu H; Xu N; Chen R; Liu S
Int J Clin Exp Pathol; 2014; 7(1):246-54. PubMed ID: 24427345
[TBL] [Abstract][Full Text] [Related]
13. Expression of collagenase-1 (MMP-1), collagenase-3 (MMP-13) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in laryngeal squamous cell carcinomas.
Krecicki T; Fraczek M; Jelen M; Podhorska M; Szkudlarek T; Zatonski T
Eur Arch Otorhinolaryngol; 2003 Oct; 260(9):494-7. PubMed ID: 12739032
[TBL] [Abstract][Full Text] [Related]
14. Serum MMP-8 and TIMP-1 as prognostic biomarkers in gastric cancer.
Laitinen A; Hagström J; Mustonen H; Kokkola A; Tervahartiala T; Sorsa T; Böckelman C; Haglund C
Tumour Biol; 2018 Sep; 40(9):1010428318799266. PubMed ID: 30192205
[TBL] [Abstract][Full Text] [Related]
15. [Assay of matrix metalloproteinase levels and their endogenous inhibitors in patients with laryngeal carcinoma].
Klisho EV; Savenkova OV; Kondakova IV; Perel'muter VM; Choĭnzonov EL; Shishkin DA
Vopr Onkol; 2007; 53(1):26-31. PubMed ID: 17649730
[TBL] [Abstract][Full Text] [Related]
16. Systemic matrix metalloproteinase-8 response in chronic tonsillitis.
Ilmarinen T; Lont T; Hagström J; Tervahartiala T; Sorsa T; Haglund C; Munck-Wickland E; Ramqvist T; Dalianis T; Aaltonen LM
Infect Dis (Lond); 2017 Apr; 49(4):302-307. PubMed ID: 27804311
[TBL] [Abstract][Full Text] [Related]
17. The prognostic role of tissue and serum MMP-1 and TIMP-1 expression in patients with non-small cell lung cancer.
An HJ; Lee YJ; Hong SA; Kim JO; Lee KY; Kim YK; Park JK; Kang JH
Pathol Res Pract; 2016 May; 212(5):357-64. PubMed ID: 26995105
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of MMP-2 in laryngeal squamous cell carcinoma: a potential indicator for poor prognosis.
Liu WW; Zeng ZY; Wu QL; Hou JH; Chen YY
Otolaryngol Head Neck Surg; 2005 Mar; 132(3):395-400. PubMed ID: 15746850
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Role of Matrix Metalloproteinases 2, 7, 8, 9 and Their Type 1 Tissue Inhibitor in Blood Serum of Patients with Kidney Cancer.
Kushlinskii NE; Gershtein ES; Alferov AA; Bezhanova SD; Mushtenko VV; Pushkar DY; Matveev VB; Stilidi IS
Bull Exp Biol Med; 2020 Mar; 168(5):673-676. PubMed ID: 32248449
[TBL] [Abstract][Full Text] [Related]
20. Serum MMP-8 and TIMP-1 predict prognosis in colorectal cancer.
Böckelman C; Beilmann-Lehtonen I; Kaprio T; Koskensalo S; Tervahartiala T; Mustonen H; Stenman UH; Sorsa T; Haglund C
BMC Cancer; 2018 Jun; 18(1):679. PubMed ID: 29929486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
